Remegen Co., Ltd.

This study compares two different drug combinations for people with advanced squamous non-small cell lung cancer who have not yet received treatment. About 574 participants will receive either a new drug called RC148 or an existing drug called tislelizumab, both combined with sta…

This study is testing whether a new drug called RC148, when combined with standard chemotherapy, works better than the current standard treatment for advanced colorectal cancer that has spread or cannot be surgically removed. It will involve about 700 adults who have not yet rece…